WASHINGTON, DC—Three-year outcomes from the ABSORB II trial, a time point in which the Absorb GT1 bioresorbable vascular scaffold should be degraded, did not result in an improvement in vasomotor tone ...
DENVER, CO—Longer-term follow-up data from the ABSORB II and III trials confirm the significantly increased risk of thrombotic events with the Absorb bioresorbable vascular scaffold (BVS; Abbott ...
Abbott said it will monitor bioabsorbable stent implantations in Europe, following a high rate of heart attacks in European Absorb GT1 patients, plus a separate FDA safety alert regarding adverse ...
Absorb, Abbott's coronary stent system made to fully dissolve in the patient's body, has finally been approved by FDA. The agency's nod comes as the device is already available in more than 100 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results